Table 3 Second-line treatment
Second-line treatment | AG (n = 24), n (%) | FFX (n = 20), n (%) |
|---|---|---|
AG | 0 | 3 (15.0) |
FFX | 2 (8.3) | 0 |
Oxaliplatin plus S1 | 3 (12.5) | 0 |
PD-1 | 3 (12.5) | 0 |
PD-1 + apatinib | 2 (8.3) | 3 (15.0) |
PD-1 + A | 1 (4.2) | 1 (5.0) |
PD-1 + gemcitabine | 0 | 1 (5.0) |
S1 or capecitabine | 4 (16.7) | 1 (5.0) |
Aptatinib or lenvatinib | 0 | 1 (5.0) |
Gemcitabine plus S1 | 0 | 1 (5.0) |
Total | 15 (62.5%) | 11 (55.0%) |